Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer

ConclusionAfter adjustment of cfDNA level,PIK3CA andTP53 mutations observed in liquid biopsy exerted detrimental effects on the outcome of ET-based regimens. The AF ofPIK3CA orTP53 may be a surrogate marker for PFS.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research